Literature DB >> 8509761

Analysis of pathotype-specific structural features and cleavage activation of Newcastle disease virus membrane glycoproteins using antipeptide antibodies.

A N Hodder1, P W Selleck, J R White, J J Gorman.   

Abstract

Peptides were synthesized, that correspond to cleaved and trimmed carboxyl termini of the F2 polypeptide regions of fusion (F) protein precursors (F0 proteins) in four different strains of Newcastle disease virus (NDV). These peptides differed only within the four carboxyl-terminal residues and represent F2 polypeptides of virulent (AV), low-virulence (EG) and avirulent (V4 and WA) pathotypes of NDV. Polyclonal rabbit antisera against each peptide reacted with their corresponding monomeric F2 polypeptides and F protein oligomers as analysed by immunoblotting of egg-propagated virions. Bidirectional cross-reactivity was observed between V4 and EG antisera and F2 polypeptides which differ only by a single variation of lysine and arginine at position 3 from their carboxyl termini. The other two antisera (AV and WA) were specific for their corresponding F2 polypeptides. All of these antisera were shown to react in a strain-specific manner with intact egg-propagated virions in an ELISA. A previously described antiserum, designed to target the haemagglutinin-neuraminidase (HN) protein precursor (HN0 protein) of avirulent strains of NDV, has been shown to be specific for residual HN0 protein of avirulent virions propagated in embryonated chicken eggs. Whereas the antiserum targeted at the carboxyl terminus of the V4 F2 polypeptide did not react with F0 proteins of cell culture-propagated strains in immunoblotting, antipeptide antibodies targeted at another region of the F2 polypeptide and a segment of the F1 polypeptide did react with the F0 protein from infected cells. These data are consistent with inclusion of the terminal carboxylate of the F2 polypeptides in the recognition determinants of the antibodies targeted at the carboxyl terminus of the V4 F2 polypeptide. The antisera described herein are ideally suited to rapid immunochemical pathotyping of NDV isolates and immunochemical characterization of the sites of intracellular cleavage activation of F0 and HN0 proteins and may be useful for defining interactions involved in F protein folding.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8509761     DOI: 10.1099/0022-1317-74-6-1081

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  HN gene C-terminal extension of Newcastle disease virus is not the determinant of the enteric tropism.

Authors:  Wei Zhao; Haixia Hu; Laszlo Zsak; Qingzhong Yu; Zengqi Yang
Journal:  Virus Genes       Date:  2013-04-03       Impact factor: 2.332

2.  Antigenic and immunogenic investigation of the virulence motif of the Newcastle disease virus fusion protein.

Authors:  Kang Seuk Choi; Eun Kyoung Lee; Woo Jin Jeon; Jun Hun Kwon
Journal:  J Vet Sci       Date:  2010-09       Impact factor: 1.672

3.  Nucleotide and predicted amino acid sequence analysis of the fusion protein and hemagglutinin-neuraminidase protein genes among Newcastle disease virus isolates. Phylogenetic relationships among the Paramyxovirinae based on attachment glycoprotein sequences.

Authors:  Bruce S Seal
Journal:  Funct Integr Genomics       Date:  2004-04-24       Impact factor: 3.410

4.  Detecting Newcastle disease virus in combination of RT-PCR with red blood cell absorption.

Authors:  Jianzhong Yi; Chengqian Liu
Journal:  Virol J       Date:  2011-05-02       Impact factor: 4.099

5.  Contribution of HN protein length diversity to Newcastle disease virus virulence, replication and biological activities.

Authors:  Jihui Jin; Jing Zhao; Yingchao Ren; Qi Zhong; Guozhong Zhang
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

6.  Effects of the HN gene C-terminal extensions on the Newcastle disease virus virulence.

Authors:  Wei Zhao; Zhenyu Zhang; Laszlo Zsak; Qingzhong Yu
Journal:  Virus Genes       Date:  2013-09-14       Impact factor: 2.198

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.